Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm41Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ansari J, Hussain SA, Ansari A, Glaholm J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b5690e7855164f9cb41a6a6e28736910
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5690e7855164f9cb41a6a6e28736910
record_format	dspace
spelling	oai:doaj.org-article:b5690e7855164f9cb41a6a6e287369102021-12-02T05:34:13ZCritical appraisal of axitinib in the treatment of advanced renal cell carcinoma1177-54751177-5491https://doaj.org/article/b5690e7855164f9cb41a6a6e287369102013-02-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-axitinib-in-the-treatment-of-advanced-renal-cell-a12320https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm41Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UKAbstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.Keywords: metastatic RCC, vascular endothelial growth factor receptor inhibitor, molecular targeted agent, clear-cell carcinomaAnsari JHussain SAAnsari AGlaholm JDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 39-46 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Ansari J Hussain SA Ansari A Glaholm J Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
description	Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm41Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UKAbstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.Keywords: metastatic RCC, vascular endothelial growth factor receptor inhibitor, molecular targeted agent, clear-cell carcinoma
format	article
author	Ansari J Hussain SA Ansari A Glaholm J
author_facet	Ansari J Hussain SA Ansari A Glaholm J
author_sort	Ansari J
title	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_short	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_full	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_fullStr	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_full_unstemmed	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_sort	critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/b5690e7855164f9cb41a6a6e28736910
work_keys_str_mv	AT ansarij criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma AT hussainsa criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma AT ansaria criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma AT glaholmj criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma
_version_	1718400371099959296

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ejemplares similares